Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7316-7321

  Makarov, Danil V ^a,b   Isharwal, Sumit ^c   Sokoll, Lori J ^c   Landis, Patricia ^c   Marlow, Cameron ^d   Epstein, Jonathan I ^c   Partin, Alan W ^c   Carter, H Ballentine ^c   Veltri, Robert W ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROPROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER SIZE; CLINICAL DECISION MAKING; COHORT ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TISSUE LEVEL; TREATMENT INDICATION; WATCHFUL WAITING;

AGED; BIOPSY; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 73149087871     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1263     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Draisma G, Boe r R, Otto SJ, e t al. Le ad times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
3. Carter HB, Kettermann A, Warlick C, et al. Expectant management of prostate cancer with curativein tent: an update of TheJo hns Hopkins Experience. J Urol 2007;178:2359-64.
4. 1c) prostate cancer. JAMA 1994;271:368-74.
5. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9.
6. Jhavar S, Bartlett J, Kovacs G, et al. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis 2009;12:143-7.
7. Khan MA, Carter HB, Epstein JI, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol 2003;170:2274-8.
8. Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling timepre dicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170-4.
9. Makarov DV, Marlow C, Epstein JI, et al. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate 2008;68:183-9.
10. Peyromaure M, Fulla Y, Debre B, Dinh-Xuan AT. Pro PSA: a "pro cancer" form of PSA? Med Hypotheses 2005;64:92-5.
11. Sokoll LJ, Wang Y, Feng Z, et al. [-2]proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Institute Early Detection Research Network validation study. J Urol 2008;180:539-43, discussion 43.
12. Peter J, Unverzagt C, Krogh TN, Vorm O, Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001;61:957-62.
13. Veltri RW, Khan MA, Marlow C, et al. Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancer. Urology 2006;68:898-904.
14. Weinzierl CF, Su SX, Pierson TB, et al. Measuring [-2]proPSA in serum: analytical performance of the Access p2PSA assay from Beckman Coulter. 2007. Abstract C-38.
15. Schroder FH. Screening, early detection, and treatment of prostate cancer: a European view. Urology 1995;46:62-70.
16. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-54.
17. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006;98:355-7.
18. Sokoll LJ, Chan DW, Mikolajczyk SD, et al. Proenzyme PSA for the early detection of prostatecance r in the 2.5-4.0 ng/mL total PSA range: preliminary analysis. Urology 2003;61:274-6.
19. Khan MA, Partin AW, Rittenhouse HG, et al. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostatespe cific antigen rangeof 4.0 to 10.0 ng/mL. J Urol 2003;170:723-6.
20. Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/mL prostate specific antigen. J Urol 2004;171:2239-44.
21. Stephan C, Kahrs AM, Cammann H, et al. A [-2] proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009;69:198-207.
22. BorreM , Stausbol-Gron B, Overgaard J. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000;164:716-21.
23. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940-4.
24. BorreM , Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcomein prostatecance r patients subjected to watchful waiting. Clin Cancer Res 2000;6:1882-90.
25. van As NJ, de Souza NM, Riches SF, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2008 [Epub ahead of print].
26. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
27. Deitch AD, Miller GJ, deVere White RW. Significanceo f abnormal diploid DNA histograms in localized prostate cancer and adjacent benign prostatic tissue. Cancer 1993;72:1692-700.
28. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 2005;5:45.
29. Parr RL, Dakubo GD, Crandall KA, et al. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 2006;8:312-9.